CytoGenix Receives Re-Supply Order for synDNA™
News Jun 14, 2006
The current order for synDNA™ was placed after the initial batch of synDNA™ proved to be the preferred material for use in the manufacture of innovative products by the client.
"The CytoGenix synDNA™ technology is ideally suited for many of our clients when conventional plasmid DNA is too costly or difficult to produce," stated Michael Chambers, President and CEO of Aldevron.
"The first order of synDNA™ met and exceeded our expectations in terms of quality, cost, and turn-around time."
"The relationship between CytoGenix and Aldevron continues to be mutually beneficial," said Malcolm Skolnick, President and CEO of CytoGenix.
"We are delighted to service clients by utilizing our excess production capacity thereby generating revenue to fund our internal product development programs."
Identical Twin Study Shows Impact of a Lifetime of Exercise on FItnessNews
When it comes to being fit, are genes or lifestyle more important? Researchers removed the nature part of the equation by studying a pair of identical twins who had taken radically different fitness paths over three decades. One became an Ironman triathlete while the other remained relatively sedentary over the last 30 years.
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
15th International Conference and Exhibition on Metabolomics & Systems
Apr 29 - Apr 30, 2019